Article: article from journal or magazin.
Diabétologie [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?]
Revue Médicale Suisse
This year, two prospective randomized studies aimed at the reduction of composite cardiovascular endpoints in type 2 diabetic patients. The PROactive study estimated the impact of pioglitazone in the secondary prevention. The significant reduction of the primary composite endpoint was not obtained: reduction of the relative risk (RR) of 10 % (p= 0.095). However, the secondary composite endpoint was significantly reduced RR 16 % (p = 0.027). The FIELD study also had the same objectives. The primary composite endpoint was not significantly reduced in spite of a RR of 11% while the reduction of RR was significant for the secondary composite endpoint (p = 0.035). These studies reveal the difficulties and the complexity of the secondary prevention of atherosclerosis for patients already treated with effective molecules.
Antilipemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Procetofen, Randomized Controlled Trials as Topic, Thiazolidinediones
Last modification date